TCGA-S3-AA12-01A-11R-A41B-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.420
- DNA_REPAIR+0.290
- MYC_TARGETS_V1+0.260
- MYC_TARGETS_V2+0.260
- E2F_TARGETS+0.150
- PEROXISOME+0.130
- ADIPOGENESIS+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.110
- BILE_ACID_METABOLISM+0.090
- MITOTIC_SPINDLE+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_GAMMA_RESPONSE-0.490
- TNFA_SIGNALING_VIA_NFKB-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- INTERFERON_ALPHA_RESPONSE-0.460
- KRAS_SIGNALING_UP-0.460
- NOTCH_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- COMPLEMENT-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NKEAAFMW | medulloblastoma | — | 0.908 |
| 2 | TCGA-86-7955-01A-11R-2187-07 | — | cohortA4 | 0.904 |
| 3 | TCGA-BH-A0HW-01A-11R-A034-07 | — | B | 0.902 |
| 4 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.894 |
| 5 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.892 |
| 6 | SRR1377445 | GTEX | — | 0.891 |
| 7 | ERR2208933 | — | — | 0.890 |
| 8 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.881 |
| 9 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.880 |
| 10 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |